TICKERNERD
Menu
BIOABIOAHealthcare · Drug Manufacturers - Specialty & Generic

BIOA Stock Forecast: BioAge Labs, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$9.59
+0.95% on the day

The 9 Wall Street analysts covering BioAge Labs, Inc. hold a median 12-month price target of $30 — +212.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 7 Sept 2026 — in the lower half.

Market cap
$440.2M
Ticker Nerd rank
41 / 100
Median analyst target
$30
Analysts covering
9
Revenue$2.5M+1.6% y/y
Operating income−$29.3M
Net income−$26.1M
Free cash flow−$19.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
−14.4%
YTD
−27.5%
1Y
+103.6%
From 52W high
−61.8%
From 52W low
+103.6%
$5
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIOA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioAge Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Momentum
69
Growth
61
Size
56
Issuance
52
Accruals
31
Quality
27
Value
25
Volatility
20

Revisions (72): Analysts have, on balance, been raising their forecasts.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIOA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIOA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26BIOAHigh $73Median $30Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $20Median $30High $73

The green dot is the last close — the median target sits +212.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026BTIGReiteratesBuy—
6 Aug 2026BTIGReiteratesBuy$40
3 Aug 2026BTIGReiteratesBuy—
3 Aug 2026BTIGReiteratesBuy$40
31 July 2026NeedhamMaintainsBuy—
31 July 2026NeedhamMaintainsBuy$50 → $35
27 May 2026Roth CapitalInitiatesBuy$36
27 May 2026Roth CapitalInitiatesBuy—
13 May 2026BTIGInitiatesBuy—
27 Mar 2026NeedhamInitiatesBuy—
10 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026OppenheimerInitiatesOutperform—
18 Feb 2026JefferiesUpgradeBuy—
27 Jan 2026Piper SandlerInitiatesOverweight—
8 Dec 2025Morgan StanleyUpgradeEqual-Weight—
29 Oct 2025CitigroupMaintainsBuy—
22 Oct 2025CitigroupUpgradeBuy—
24 Mar 2025CitigroupMaintainsNeutral—
7 Mar 2025Morgan StanleyAssumesUnderweight$5.00
28 Feb 2025William BlairInitiatesMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIOA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BIOA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, BioAge Labs, Inc. returned +103.6% against +20.0% for the S&P 500, dividends included.

BIOA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26BIOAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BIOA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

BioAge Labs, Inc. (BIOA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.4×

Cheaper than 70% of US stocks

Price / sales
42.5×

Cheaper than 6% of US stocks

Price / book
1.2×

Cheaper than 69% of US stocks

EV / EBITDA
−1.2×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
1.6%

Higher than 31% of US stocks

Earnings growth (YoY)
1.6%

Higher than 38% of US stocks

Gross margin
—
Operating margin
−1196.8%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.2%

Higher than 28% of US stocks

Return on assets
−18.5%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioAge Labs, Inc. (BIOA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioAge Labs, Inc. has a market value of $440.2M and an enterprise value of $124.2M.

  • Revenue in the twelve months to 30 June 2026: $10.4M. The latest quarter grew 1.6% year on year.

  • Net income over the same four quarters: −$94.5M, a −912.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$88.1M.

  • Shares outstanding: 45.8M.

  • Trailing P/E: 1.4×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioAge Labs, Inc. employs 60 people — $173K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

BIOA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BIOABioAge Labs, Inc.$440.2M
41
CGCCanopy Growth Corp.$439.5M
46
TKNOAlpha Teknova, Inc.$371.0M
93
KMDAKamada Ltd.$500.9M
96
EBSEmergent BioSolutions, Inc.$321.5M
89
EOLSEvolus, Inc.$605.1M
86
TLRYTilray Brands, Inc.$612.9M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioAge Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIOA news & analysis

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

GlobeNewsWire · 8 Sept 2026positive

BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, a novel NLRP3 inhibitor, in adults with diabetic macular edema. The approximately 180-participant trial will evaluate BGE-102 as monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.

Why it matters — This milestone advances BioAge's BGE-102 program in diabetic macular edema and will inform its development strategy in other NLRP3-driven retinal diseases, including geographic atrophy, potentially broadening its pipeline beyond cardiometabolic indications.

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

Seeking Alpha · 5 Sept 2026positive

BioAge Labs' shares fell over 40% partly due to a sell-off triggered by rivals' data, despite competitive Phase 1 results for its NLRP3 inhibitor BGE-102, which achieved up to 98% IL-1β suppression and 86% median hsCRP reduction. The article views the sell-off as overblown, citing Phase 2 topline data expected in H2 2026 and a diversified pipeline of ophthalmology, apelin-APJ programs, and partnerships with Novartis and Eli Lilly.

Why it matters — A BIOA watcher would care because the item frames the recent stock drop as an overreaction, highlighting expected Phase 2 data for BGE-102 in H2 2026 and a diversified pipeline and partnerships that support long-term optionality.

BioAge Labs to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

BioAge Labs announced that it will participate in several upcoming investor conferences. The clinical-stage biotechnology company develops therapeutic candidates for cardiometabolic diseases by targeting the biology of human aging.

Why it matters — Conference participation gives investors and analysts additional opportunities to hear updates about BioAge's pipeline and strategy.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

BioAge Labs reported a quarterly loss of $0.58 per share for Q2, narrower than the Zacks Consensus Estimate of a $0.65 loss and slightly better than the $0.6 per-share loss a year ago. The company also beat revenue estimates.

Why it matters — A BIOA watcher would care because the company's quarterly loss came in better than analyst expectations, indicating results were stronger than consensus forecast.

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 5 Aug 2026neutral

BioAge Labs reported its second quarter 2026 financial results and provided business updates. The update noted that the first participant has been dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers, with topline data anticipated in the second half of 2026.

Why it matters — The QueLL-CV trial enrollment start for BGE-102 and the expected topline readout in the second half of 2026 represent a key upcoming clinical milestone for BIOA watchers.

FAQ

Frequently asked questions about BIOA stock

What is the BIOA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering BioAge Labs, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIOA stock a buy right now?

Of the 9 analysts covering BioAge Labs, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioAge Labs, Inc. 41 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIOA?

As at 7 Sept 2026, BioAge Labs, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will BIOA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +212.8% from the last close, and Ticker Nerd's factor model ranks BioAge Labs, Inc. 41 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIOA stock forecast for 2030?

No analyst covering BioAge Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIOA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $73 over the next 12 months.

How has BIOA stock performed over the past year?

BioAge Labs, Inc. returned +103.6% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioAge Labs, Inc. do?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging.

What is the latest news on BIOA?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema". BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, a novel NLRP3 inhibitor, in adults with diabetic macular edema. The approximately 180-participant trial will evaluate BGE-102 as monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.

Company

About BioAge Labs, Inc.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. BioAge Labs, Inc. advances a pipeline of product candidates designed to address conditions such as obesity and other age-associated disorders, using human data and molecular insights to identify drug targets linked to healthy aging. Its current programs include orally available small-molecule candidates and inhibitors aimed at cardiometabolic and neuroinflammatory disease pathways. The company’s work spans therapeutic development in obesity, cardiovascular risk, retinal disorders, and other metabolic indications, positioning it as a research-driven participant in the biotechnology sector. BioAge Labs, Inc. operates with a translational approach that connects aging biology to drug discovery, supporting the development of medicines intended to treat diseases with common biological mechanisms.

CEO Dr. Kristen Fortney Ph.D. · 60 employees · United States · https://bioagelabs.com